Derek Heimlich
Optometrist · Blue Ash, OHNPI 1699393090
Payments from drug & device makers
Across 122 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$570
- Apellis Pharmaceuticals, Inc.$388
- Bausch & Lomb Americas Inc.$356
- Tarsus Pharmaceuticals, Inc.$354
- Alcon$287
- Regeneron Healthcare Solutions, Inc.$211
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,41498%
- Education$632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $570 |
| Apellis Pharmaceuticals, Inc. | 15 | $388 |
| Bausch & Lomb Americas Inc. | 12 | $356 |
| Tarsus Pharmaceuticals, Inc. | 9 | $354 |
| Alcon | 10 | $287 |
| Regeneron Healthcare Solutions, Inc. | 7 | $211 |
| Oyster Point Pharma, Inc. | 4 | $187 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Alimera Sciences, Inc. | 6 | $123 |
| Biotissue Holdings Inc. | 4 | $120 |
| Genentech USA, Inc. | 5 | $112 |
| Harrow Eye, LLC | 5 | $106 |
| Dompe US, Inc. | 2 | $91 |
| Astellas Pharma US Inc | 4 | $88 |
| Novartis | 4 | $64 |
| Ivantis, Inc | 4 | $63 |
| Sun Pharmaceutical Industries Inc. | 3 | $49 |
| Amgen(2 entities) | 3 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Thea Pharma Inc. | 1 | $26 |
| Coherus Oncology, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Glaukos Corporation | 1 | $21 |
| Eyepoint US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,477 in reported general payments places this provider in the 85th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 36 | $68,359 |
| RestasisCyclosporine | 68 | $66,064 |
| LumiganBimatoprost | 74 | $37,699 |
| RocklatanNetarsudil Mesylat/Latanoprost | 55 | $35,923 |
| RhopressaNetarsudil Mesylate | 29 | $22,236 |
| XiidraLifitegrast | 19 | $19,442 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 74 | $11,733 |
| Latanoprost | 1,302 | $10,423 |
| Brimonidine Tartrate | 766 | $9,776 |
| Alphagan PBrimonidine Tartrate | 40 | $9,306 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 619 | $7,057 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $5,146 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 34 | $4,206 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $2,995 |
| Dorzolamide Hcl | 200 | $2,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $570 | $116,064196 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $354 | $68,35936 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $124 | $58,15984 claims |
| Bausch & Lomb Americas Inc.Xiidra | $356 | $19,44219 claims |
| AlconSimbrinza | $287 | $5,14625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Blue Ash
- Daniel HageeBlue Ash$58K
- Katherine BickleGranville$3M
- Jennifer FogtColumbus$1.9M
- Jason MillerPowell$1.4M
- Mile BrujicBowling Green$1.3M
- William LayWesterville$891K
- Gregory DenaeyerColumbus$846K
- Thomas ChesterCleveland$786K
- Loretta Szczotka-FlynnCleveland$388K
- Cory LappinMontgomery$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.